Skip Navigation


JAC Advance Access originally published online on June 14, 2005
Journal of Antimicrobial Chemotherapy 2005 56(2):440-441; doi:10.1093/jac/dki202
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/2/440    most recent
dki202v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (3)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Grau, S.
Right arrow Articles by Alvarez-Lerma, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Grau, S.
Right arrow Articles by Alvarez-Lerma, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Correspondence

Linezolid: low pre-treatment platelet values could increase the risk of thrombocytopenia

Santiago Grau*, José A. Morales-Molina, Javier Mateu-de Antonio, Mónica Marín-Casino and Francisco Alvarez-Lerma

Hospital del Mar, Passeig Marítim, 25–29, 08003 Barcelona, Spain

* Corresponding author. Tel: +34-93-248-30-00; Fax: +34-93-248-32-56; E-mail: sgrau@imas.imim.es

Keywords: oxazolidinones , toxicity , platelet count , critical illness

The first 10% of the full text of this article appears below.

Sir,

Recently, Senneville et al.1 published a study including 45 patients with prolonged linezolid therapy (4 weeks or longer) for chronic osteomyelitis in whom risk factors for anaemia were assessed. The authors found that two independent risk factors were associated with anaemia: age >58 years and low pre-treatment haemoglobin. Patients who developed anaemia presented nearly 17 times more frequently with pre-treatment haemoglobin less than 10.5 g/dL (P = 0.04).

In similar work, we have studied prospectively 49 critical non-thrombocytopenic patients . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
S. A. Grim, L. Rene, S. Gupta, and N. M. Clark
Safety of linezolid in patients with baseline thrombocytopenia
J. Antimicrob. Chemother., October 1, 2008; 62(4): 850 - 851.
[Full Text] [PDF]